Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Babraham Scientists Establish Cancer-Focussed Collaboration with AstraZeneca

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Partnership aims to advance cancer research and develop and evaluate new therapeutic strategies to tackle prostate and pancreatic cancers.

Other projects between the partners will study cancer tumour mutations and aim to better understand how the genetic makeup of an individual patient's cancer determines their response to treatment.

This represents a significant alliance between scientists from AstraZeneca's small molecule and MedImmune's biologics units and members of the Cambridge Cancer Centre, which brings together researchers across the region from the University, affiliated Institutes and the NHS.

Pancreatic cancer is the fifth most common cause of cancer death in the UK and has an extremely poor prognosis and few treatments are currently available. Developing methods for earlier detection and new therapeutic strategies are crucial if survival rates, which have improved little in the last forty years, are to improve.

Babraham Scientists, together with Cancer Research UK Cambridge Institute, the Cambridge University Department of Oncology at Addenbrooke's Hospital and Cambridge University Hospitals NHS Foundation Trust, will be evaluating new therapeutic approaches for pancreatic cancer patients. It is hoped that this two year collaboration on pre-clinical and clinical oncology projects between researchers and clinicians, will identify the best drug combination partners for AstraZeneca's investigational compound selumetinib in pre-clinical models.

Selumetinib, a molecule known as a MEK inhibitor, halts the activity of a particular biochemical signalling pathways within cells that are often overactive in certain cancers. It has been shown in Phase I/II studies to be clinically active and is tolerated, as both monotherapy and in combination with other chemotherapy regimens, in clinical studies across a range of solid tumours.

Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit said, "These are the first research collaborations AstraZeneca has signed with Cambridge-based partners since announcing our intention to build a world-class research and development centre on the Cambridge Biomedical Campus. It is fitting that the focus of these collaborations is on delivering new medicines for cancer because our Cambridge facility will represent AstraZeneca's largest centre for oncology research. We look forward to having our scientists work side-by-side with some of the UK's most distinguished medical institutions.

"All three of the collaborations we are announcing today advance our work in the area of personalised healthcare, helping us to understand and address the underlying mechanisms of disease so that we can find the right medicines for the right patients."

Dr Claire Cockcroft, Babraham's Knowledge Exchange Manager said, "Collaborative partnerships between world-leading research organisations, industry, clinicians and NHS centres will play an increasingly critical role driving the development of novel therapies and evaluating drug targets to address unmet healthcare challenges and improve patient wellbeing. Working together to increase understanding of the basic biology underpinning mechanisms of drug action and how patients respond to treatments will bring a more personalised approach to healthcare, where genome-based information will enable patients to be matched to the most appropriate treatments."

David Neal, Group Leader at the Cancer Research UK Cambridge Institute and Honorary consultant Urological Surgeon at Addenbrooke's Hospital, said, "I am delighted about this partnership on the Biomedical Campus between AstraZeneca, the Cancer Research UK Cambridge Institute and the Cambridge University Department of Oncology at Addenbrooke's Hospital. It is a wonderful example of how collaboration between world-class Pharma and cutting edge Science will lead to benefits for patients through better understanding individual variation in cancer behavior."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genome-Editing Position Statement
A group of leading UK research organisations has today issued an initial joint statement in support of the continued use of CRISPR-Cas9 and other genome-editing techniques in preclinical research.
Monday, September 07, 2015
Expanding the DNA Alphabet: 'Extra' DNA Base Found to be Stable in Mammals
A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
Thursday, June 25, 2015
Researchers Use ‘Big Data’ Approach to Map the Relationships Between Human and Animal Diseases
EID2 database used to prevent and tackle disease outbreaks around the globe.
Thursday, July 17, 2014
TGAC at the Forefront of Next Generation Sequencing Capability
The Genome Analysis Centre adds two Illumina HiSeq 2500 machines to its platform suite.
Thursday, June 26, 2014
£12M for Synthetic Biology Facilities and Training
The UK Research Councils, led by the BBSRC, will award £10M to establish five centres for DNA synthesis across the UK to further develop the UK's research base in synthetic biology.
Monday, April 07, 2014
Scientists identify ‘long distance scanner’ for DNA damage
BBSRC-funded scientists at the University of Bristol have discovered that a mechanism for preventing mutation within important genes involves long distance scanning of DNA by a molecular motor protein.
Wednesday, February 26, 2014
UK Establishes Three New Synthetic Biology Research Centres
Bristol, Nottingham and a Cambridge/Norwich partnership will be UK centres for synthetic biology.
Friday, January 31, 2014
New Chromosome Map Points the Way Through Campylobacter’s Genetic Controls
The Institute of Food Research has produced a new map of the Campylobacter genome, showing the points where all of this pathogenic bacteria's genes are turned on.
Wednesday, November 13, 2013
BBSRC Invests £10 M in Synthetic Biology
The investment has been allocated to the fund by the BBSRC in response to the 2012 Synthetic Biology Roadmap, which sets out plans to harness opportunities in this area.
Thursday, November 07, 2013
A Community Based Approach for Tackling the Post-Genomic Data Deluge
Correspondence highlights the benefits of a community approach to gathering data that can help improve our understanding of the functions of genes.
Monday, October 14, 2013
‘X-Shape’ Not True Picture of Chromosome Structure, New Imaging Technique Reveals
First 3D pictures of chromosome structure revealed.
Friday, September 27, 2013
Moving Genes have Scientists Seeing Spots
An international team of scientists has perfected a way of watching genes move within a living plant cell.
Wednesday, September 11, 2013
Advance in Understanding Genome Reproduction
Researchers have provided new insight into how chromosome integrity is threatened each time a cell grows and divides, helping to underpin our knowledge of healthy aging.
Thursday, August 01, 2013
£60,000 Competition to Recognise Innovative Scientists Launched by BBSRC
Innovator of the Year 2014 competition launched by BBSRC to recognise and reward scientist's whose excellent science and innovations are delivering real world impact.
Friday, July 12, 2013
Pig Disease that Costs Millions Targeted by Genetic Study
A fast mutating virus that affects pig herds and costs pork producers millions of pounds each year is being targeted by scientists.
Thursday, April 11, 2013
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!